ImmunityBio

Inducing Immunogenic Cell Death By Orchestrating the Innate (NK) and Adaptive (T Cell) Immune System

Careers

Join our fast-growing immunotherapy company. We offer you the chance to work with a team that is focused on building something impactful.

About Us

ImmunityBio, Inc. is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.

Recent News

Mar. 10, 2020
ImmunityBio Announces Durable Virus Control of SHIV Without Anti-Retroviral Therapy by Activating NK and Memory T Cells with N-803, an IL-15 Superagonist

Recent News

Mar. 10, 2020
ImmunityBio Announces Durable Virus Control of SHIV Without Anti-Retroviral Therapy by Activating NK and Memory T Cells with N-803, an IL-15 Superagonist

About Us

ImmunityBio, Inc. is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.

Careers

Join our fast-growing immunotherapy company. We offer you the chance to work with a team that is focused on building something impactful.

Contact Us

ImmunityBio, Inc.

© 2020 ImmunityBio, Inc. All rights reserved.

Privacy | Terms of Use.

© 2020 ImmunityBio, Inc. All rights reserved.

Privacy | Terms of Use.